Taiwan Biotech Achieves Record Cross-Border Deals, Boosting Global Competitiveness

Taiwan’s biotechnology industry is gaining new momentum through international collaborations, as two local companies recently achieved significant milestones in global partnerships. Jianqiao Technology (TWSE: 2001) has signed an exclusive licensing agreement with Japanese pharmaceutical company Nxera Pharma, securing the rights to license and commercialize an insomnia medication across eight markets in the Asia-Pacific region. This move not only expands Jianqiao’s product portfolio but also enables rapid market entry in key regions, including Southeast Asia and Japan. As a critical drug in the chronic disease sector, the market for insomnia medications is projected to grow at an annual rate of 8% over the next five years, positioning Jianqiao to capture long-term revenue streams.

Qihong Biotechnology, meanwhile, is focusing on the gene therapy sector, collaborating with Japanese firms such as ONODERA GT Pharma and TOKIWA Bio on contract development and manufacturing of gene therapies, as well as biosafety testing. Given the high degree of specialization and substantial R&D costs associated with gene therapy, such initiatives typically require the integration of diverse resources. By partnering with Japanese companies for technology and funding, Qihong can mitigate R&D risks while accelerating product launch. This collaborative model has become a key strategy globally for driving rapid progress in gene therapy, offering Taiwanese enterprises the opportunity to secure a foothold in the global market.

The collaborative strategies adopted by both companies reflect Taiwan’s biotech sector’s gradual shift from single-technology R&D toward diversified business models. Through the insomnia drug licensing deal, Jianqiao has gained more comprehensive control over the entire value chain, including drug licensing, manufacturing, and marketing. Qihong, utilizing a contract development model, concentrates its R&D efforts on core technologies and clinical validation, while outsourcing manufacturing and safety testing to specialized Japanese firms. This model of "internal and external synergy" helps Taiwanese companies reduce costs, accelerate time-to-market, and enhance their competitiveness in global markets.

Furthermore, these cross-border collaborations are positively impacting Taiwan’s broader industrial chain. Under the insomnia drug licensing agreement, Jianqiao will expand its sales network across the Asia-Pacific region, driving demand for related pharmaceutical logistics, warehousing, and medical distribution channels. Qihong’s contract development in gene therapy requires high-end manufacturing equipment, clinical trial facilities, and regulatory compliance teams, which will promote the upgrading of Taiwan’s related industries and talent development. If the government supports these efforts with relevant policies, such as tax incentives, R&D subsidies, and regulatory streamlining, it will further stimulate local enterprises’ enthusiasm for international cooperation.

Ultimately, these two partnerships represent not only corporate successes but also significant milestones for Taiwan’s biotech industry in seeking breakthroughs in the global market. As the international pharmaceutical market continues to expand, Taiwanese companies that consistently deepen cross-border collaborations, strengthen technological barriers, and enhance brand influence will be well-positioned to occupy a more competitive niche on the global pharmaceutical stage. (Source: CNA)